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The Drug Effectiveness Review Project was initiated in 2003 in response to dramatic increases in the cost of
pharmaceuticals, which lessened the purchasing power of state Medicaid budgets. A collaborative group of state
Medicaid agencies and other organizations formed to commission high-quality comparative effectiveness reviews
to inform evidence-based decisions about drugs that would be available to Medicaid recipients. The Project is
coordinated by the Center for Evidence-based Policy (CEbP) at Oregon Health & Science University (OHSU), and the
systematic reviews are undertaken by the Evidence-based Practice Centers (EPCs) at OHSU and at the University of
North Carolina. The reviews adhere to high standards for comparative effectiveness reviews. Because the
investigators have direct, regular communication with policy-makers, the reports have direct impact on policy and
decision-making, unlike many systematic reviews. The Project was an innovator of methods to involve stakeholders
and continues to develop its methods in conducting reviews that are highly relevant to policy-makers. The
methods used for selecting topics, developing key questions, searching, determining eligibility of studies, assessing
study quality, conducting qualitative and quantitative syntheses, rating the strength of evidence, and summarizing
findings are described. In addition, our on-going interactions with the policy-makers that use the reports are
described.Background
Created from efforts to improve formulary policy for the
Oregon Health Plan (OHP) – Oregon’s innovative Me-
dicaid program – the Drug Effectiveness Review Project
(DERP) now has almost a decade of experience conduct-
ing comparative effectiveness research to determine
what works best in the effort to inform health policy
decisions with evidence. Recent health care legislation
and, in particular, the creation of the Patient-Centered
Outcomes Research Institute (PCORI) make this experi-
ence increasingly relevant to the national effort to make
better and more cost-effective health policy.
By 2001, a rapid increase in the cost of medications [1]
had contributed to skyrocketing budgets for the
expanded OHP. Governor John Kitzhaber, an emergency
room physician by training and a creator of the OHP,
believed the application of an evidence-based process* Correspondence: mcdonagh@ohsu.edu
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distribution, and reproduction in any mediumwould improve health and financial outcomes. Kitzhaber
argued that doctors don't have the necessary, unbiased
drug comparison studies to help them make choices that
are both medically sound and cost effective. These
choices should be based on true comparative effective-
ness evidence. Cost would be considered primarily
where no clinically important differences in benefit or
harm were found.
At the outset, the Oregon Evidence-based Practice
Center (EPC) was asked to conduct systematic reviews
of several classes of drugs; each class contained multiple
expensive drugs and thus a potential for increased bene-
fit, reduced harm, reduced cost, or a combination of
these. EPC investigators met with the relevant State
appointed topic-specific committees (comprising of clin-
icians and community representatives) initially to de-
velop the key questions and later to provide an overview
of the findings and to answer questions. These meetings
were held publicly and public testimony was allowed;
typically a few physicians, patients (or caregivers), and
representatives of pharmaceutical companies attended.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
McDonagh et al. BMC Medical Research Methodology 2012, 12:140 Page 2 of 11
http://www.biomedcentral.com/1471-2288/12/140The committees made recommendations to the Health
Resources Commission, who in turn, made final recom-
mendations to the state Medicaid agency.
Oregon reaped early success with this process: In 2001
a systematic review showed that among the five proton
pump inhibitors available, there were no clear differ-
ences in benefits or harms between medications [2].
The State ultimately listed only the three least expensive
drugs as “preferred.” On the basis of this and other
early successes, state Medicaid agencies in Idaho and
Washington joined Oregon to commission further
research.
After leaving office in 2003, Kitzhaber formed the
Center for Evidence-based Policy (CEbP) at Oregon
Health and Science University (OHSU). The first CEbP
project was an expansion of the alliance of Medicaid
agencies. In all, 15 organizations – 14 state Medicaid
agencies and the Canadian Office for Health Technology
Assessment (now the Canadian Agency for Drugs and
Technologies in Health) – formed the collaboration that
became the DERP (Figure 1). Currently, EPC researchers
from OHSU and the University of North Carolina
provide comparative effectiveness reviews for DERP.
Over its lifespan, DERP has evolved methodologies
to evaluate comparative evidence on the balance of
drug therapy benefits and harms and to disseminate
systematic reviews of that evidence in collaboration with
a highly engaged stakeholder group. DERP’s regular
interaction with policy-makers who use the reviews, its
experience in determining when topics require updating,
and its incorporation of emerging methodological
standards, places DERP in a unique position to inform
the recent initiatives in comparative effectiveness re-
search. The purpose of this paper is to give an overview
of the current methods of evidence review and dissemin-
ation used by the two EPCs producing DERP reports.
Overview of DERP systematic review process
Below is a description of the processes used in produ-
cing DERP reports. The overall process and timelines
are shown in Figure 2.
Conflict of interest policy
DERP investigators and their staff comply with a policy
on conflicts of interest that includes a formal, annual,
written self-declaration of no financial interest (defined
as direct ownership of stock, research funding, or fees
for speaker’s bureaus or consulting) in any pharmaceut-
ical company for at least the duration of the time the
person is doing work for DERP. We have found that this
policy, which is much more restrictive than those at
other organizations where modest interests are allowed
with disclosure, both simplifies interactions with teams
and reassures the stakeholders. At the same time,engagement with industry is a critical part of the DERP
process as described below.Selection of topics
Organizations participating in DERP follow an explicit
process to ensure equal opportunity for input in the se-
lection of topics for systematic review. The CEbP solicits
topics from each organization, typically on an annual
basis. After discussing each nomination, the organiza-
tions select up to five topics for further workup. Limiting
to five topics reflects the workload required to prepare
topic briefs, the limited resources available for conduct-
ing research, and the improved level of discussion with
fewer choices. Consisting of the original submission
details, a summary of pros and cons, and an overview of
available systematic reviews and randomized trials, this
workup is used to inform organizations as to whether
sufficient evidence is available to support a full review.
Over the years, the content of these briefing papers has
evolved. For example, previous versions asked participat-
ing organizations to estimate the level of use and poten-
tial economic impact of the proposed drugs in their
respective programs. Because this was not always pos-
sible to do, and created additional workload, this aspect
was changed to a more qualitative question about pros
and cons. To identify high-quality systematic reviews
relevant to the proposed topic, the EPC investigators
search MEDLINE and the Web sites for Agency for
Healthcare Research and Quality (AHRQ), the Canadian
Agency for Drugs and Technologies in Health, the
Cochrane Collaboration, and the National Coordinating
Center for Health Technology Assessment, the National
Institute for Clinical Excellence, and the Center for
Reviews and Dissemination. Identification of an existing
recent high-quality review may indicate that it is not ne-
cessary to undertake a new review and the number of
trials is an indicator of the volume of the evidence on a
topic. At a face-to-face meeting, participating organiza-
tions discuss the briefing papers and select topics for
which DERP reports will be commissioned.Formulation of key questions
Key questions define the scope of a DERP report. Pre-
liminary key questions are formulated by EPC investiga-
tors on the basis of the discussion that led to the topic
selection. Participating organizations review the draft
key questions and clinical experts, described below, are
consulted. After modifications, the draft key questions
are posted to the DERP Web site for public comment.
Public comments and responses proposed by investiga-
tors are discussed with the participating organizations.
Our records indicate that we receive a mean of 2.5 sets
of comments per posting.
GOVERNANCE GROUP
12 to 17 Participating Organizations
Oregon EPC Conducts Reviews
Oregon EPC Coordinates Scientific Work
Center for Evidence Based Policy
Administers, Coordinates Governance Processes
North Carolina EPC Conducts Reviews
Figure 1 DERP organizational structure.
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pating organizations, the final key questions and related
eligibility criteria, which will define the scope of the up-
coming report, are posted to the DERP Web site. The
eligibility criteria specify the Populations, Interventions,
Comparisons, Outcomes, Timing, Settings and Study
designs or characteristics (PICOTS) of interest. Each of
the PICOTS is selected to reflect participant needs. For
example, the list of interventions is selected to reflect
the drugs under consideration by participating Medicaid
agencies and similar drugs available in Canada. In DERP,
the primary outcomes of interest are health outcomes
reflecting effectiveness rather than short-term efficacy
outcomes (e.g., intermediate or surrogate outcomes).
However, there are examples where intermediate out-
comes are valuable to policy-making and these are
included on a case-by-case basis (e.g., LDLc for statins).
Eligible harms outcomes typically include overall rates of
adverse events (AEs), withdrawal due to AEs, and AEs
specific to the drug class, including serious AEs. Anexample of a set of final key questions and eligibility cri-
teria are shown in Figure 3.
Input of clinical advisors
The Clinical Advisory Group provides clinically relevant
counsel throughout the development of a report. We began
using such an advisory group in 2007, and they are con-
vened for all original reports on new topics. For updates of
existing DERP reports, advisory groups are formed on a
case-by-case basis, depending largely on whether a substan-
tial change in scope has occurred between the previous re-
port and the pending update. Prior to 2007, we consulted
with clinicians on an ad hoc basis.
The CEbP identifies potential clinical advisors among
clinicians suggested by the participating organizations,
which recommend clinical experts who best represent
their constituencies and who also have significant recent
experience in direct patient care. The participating organi-
zations review the qualifications and declared conflicts of
interest of the group prior to selecting the group’s final
Figure 2 DERP report process and timelines. *Depending on funds remaining.
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on conflicts of interest, if conflicts are declared members
are selected with these in mind, in an effort to compile a
group with balanced interests. Members of the Clinical
Advisory Group are not compensated for their time, typic-
ally two to eight hours each, excluding time spent review-
ing the draft report if they serve as a peer reviewer. Their
names are listed both in the report and on the DERP Web
site.
Searching for literature
Searches of electronic databases are conducted in consult-
ation with an information specialist. All DERP reports en-
tail, at minimum, a search of Ovid Medline – or PubMed –and the Cochrane Library. Other databases (e.g., Embase
and PsycINFO) are searched depending on availability to
the EPC conducting the review and on the topic of the
report (e.g. PsychINFO is searched for topics that include
psychiatric indications). Search strategies generally combine
all included interventions (using proprietary and generic
names) and populations. Literature searches are repeated
2 to 3 months before submission of the draft report.
Additionally, references of key papers are searched by hand.
Pharmaceutical companies
The CEbP requests information from all pharmaceutical
companies that manufacture a drug included in a DERP
report. We request a complete list of citations for all
Figure 3 Final key questions and eligibility criteria.
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also request information on unpublished studies or un-
published data relating to a published study, with the
understanding that once the report is published the pub-
lic may obtain the information by requesting a copy of
the information submitted. An accounting of companies
providing information is included in the report. We have
received over 100 submissions since DERP began.US Food and Drug Administration (FDA)
The FDA Center for Drug Evaluation and Research
“Drugs@FDA” Web site is searched for statistical and
medical reviews written by FDA personnel about drugs
approved for specific indications. These reviews contain
information about trials submitted by pharmaceutical
companies as part of New Drug Applications, including
study design, results, and analysis of results. We compare
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published literature to identify additional unpublished
studies or data, including identifying variation in out-
comes reporting. FDA documents may not be available
for every drug included in DERP reports: posting of a
new drug’s documents to the Web site has sometimes
been delayed despite approval of the drug and the Web
site does not generally contain documents related to
drugs approved before 1997.
Eligible study designs
For a study to be selected for inclusion, it must meet all
eligibility criteria, as described above, including study
designs, as explicitly specified a priori. Studies with
results presented only in a language other than English
are excluded because of resource limitations. Studies
reported only in conference abstracts are excluded be-
cause experience has shown us that typically there is in-
adequate information provided to evaluate study quality,
including selective reporting of results, and to match up
multiple abstracts related to a single unique study.
Head-to-head trials
Randomized controlled trials directly comparing two or
more drugs in the review are included to evaluate both
benefit and harms outcomes.
Observational studies
Our methods for decisions on including observational
studies concur with the recently published guidance for
the AHRQ Effective Healthcare Program [3,4]. Head-to-
head cohort studies and case-control studies are
included in all DERP reports to assess harms [3-6].
These types of studies are also included to evaluate ben-
efits where trial evidence flaws are known or suspected
(e.g., trial evidence includes such narrowly defined popu-
lations, outcome measures, or interventions and controls
that it has limited usefulness). In our reports on drugs to
treat attention deficit hyperactivity disorder (ADHD), we
made the decision to include observational studies for
benefit outcomes because the trials 1) were largely con-
ducted in controlled classroom settings, 2) enrolled chil-
dren with few or no comorbidities, and 3) did not report
“real life” outcomes, such as academic progress or suc-
cess [7]. While all DERP reviews include observational
studies to assess harms, to date seven also include them
to assess benefits.
Systematic reviews
Existing systematic reviews that directly address the key
questions and meet minimum standards for quality are
considered for inclusion. Reviews must meet the follow-
ing minimum criteria to be considered systematic: The
review must include a comprehensive search for evidencefrom multiple sources of information (electronic data-
bases, reference lists, etc.), describe the terms used in the
search (in some way), and use dual review of studies for
inclusion. The review must address questions that are
similar enough to the key question to provide useful in-
formation; reviews that examine a class effect or only a
portion of the drugs in a class are unlikely to be useful in
a DERP report. For example, while we identified many
prior systematic reviews of atypical antipsychotic drugs,
none made comparisons of all drugs in the group to each
other [8]. Most compared only olanzapine and risperi-
done, or compared the atypical drugs to the older, con-
ventional antipsychotic drugs. A cut-off date is selected
(e.g., two years) based on how much the field has chan-
ged in the intervening period. With atypical antipsycho-
tics, the reviews identified were outdated and new
studies and new drugs needed to be considered.
Placebo-controlled trials
Where there are gaps in direct comparative evidence, we
consider including placebo-controlled trials for indirect
comparisons of benefits and harms. The decision to pur-
sue a quantitative indirect comparison takes into account
the degree of clinical, methodological, and statistical het-
erogeneity across the studies under consideration. We
follow established guidance on methods for quantitative
indirect synthesis [3,9-14].
When indirect comparisons are not undertaken, find-
ings from placebo-controlled trials can be discussed to
identify individual drugs with evidence of benefit (and to
identify the magnitude of effect) and those with no such
evidence.
Study-level pooled analyses
“Pooled analyses” is our term for published meta-
analyses that are not based on a comprehensive litera-
ture search and do not include assessment of the quality
of individual studies. Pooled analyses differ from system-
atic reviews that utilize meta-analysis as part of the syn-
thesis of evidence (e.g. DERP reports) and potentially
introduce bias. Therefore, as with placebo-controlled
trials, pooled analyses are considered for inclusion in
DERP reports only where other evidence is absent or in-
sufficient. An example is where the only information
about a subgroup of patients available is from a pooled
analysis of data from manufacturer-sponsored trials.
Single-group studies
Studies without a well-formed comparison group have a
high risk of bias, particularly in assessing benefit [4].
Single-group studies may be included to evaluate harms
under the “best evidence” approach only if the studies
add important evidence on harms that is not available
from study designs with lower risk of bias. To be useful
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size and duration of drug exposure that is both longer
than the exposure in existing trials (e.g. where trials
range from a few weeks to several months but single-
group studies report a year or more of exposure) and
long enough for AEs that take time to develop to occur
(e.g. cancer). We often depend on the clinical experience
of our advisors to determine the required length of ob-
servation required for a given AE, because it can be diffi-
cult to make an objective determination. Such studies
may have included patients with a broader range of
comorbidities, increasing applicability.
Open-label extension studies have limited applicability
and higher risk of bias than do the original trials. These
study populations are derived from clinical trials, where
patients are already winnowed to meet a narrow set of
eligibility criteria, and patients in the extension often are
those who had an adequate drug response and tolerance
during the trial period. An extension study without a
comparison group is especially subject to bias, becoming
essentially an observational study in a highly selected
population. As such, we include them only under the
conditions stated above, but view them as reflecting a
very narrowly defined population.
Unpublished studies or data
Unpublished studies (e.g. information submitted by
manufacturers, FDA documents, or trial registries that
include results) may be included if they meet eligibility
criteria and provide sufficient detail to assess study qual-
ity. At minimum, information must be provided on the
comparability of groups at baseline, attrition, number of
patients analyzed, the statistical tests used for data ana-
lysis, and whether an intention-to-treat analysis was con-
ducted. When a manufacturer provides additional
unpublished outcomes or subgroup data from a pub-
lished study, these data will be included if 1) the study is
a direct, head-to-head comparison of included drugs,
and 2) the study reports the statistical tests used for data
analysis, attrition, numbers of patients analyzed in each
group, and whether an intention-to-treat analysis was
conducted. Prior to 2010, inclusion criteria were deter-
mined on a case-by-case basis by each review team,
largely based on the ability to conduct a quality assess-
ment. Experience such as the limited usefulness of in-
cluding various post-hoc subgroup data submitted by
industry for our fixed dose combination products review
led us to tighten and formalize these criteria in 2010
[15].
Determining eligibility of studies
In order to reduce potential reviewer bias and ensure ac-
curacy and reproducibility, all study reports identified in
literature searches are assessed for eligibility by twoinvestigators. Before full-text studies are assessed, titles
and abstracts identified by searches are evaluated. For
this evaluation one investigator may complete eligibility
assessments with a second reviewer evaluating only
those studies that the first investigator chose to exclude.
With this “carry-forward” strategy, only studies that are
unequivocally ineligible are rejected at this stage. Full-
text articles of potentially relevant citations are retrieved
and dually assessed for inclusion by two reviewers. Dis-
agreements are resolved through consensus. In accord-
ance with recommendations on reporting, a diagram
indicating the flow of inclusion and exclusion of studies
is presented [16]. Excluded trials, along with the reason
for exclusion, are listed in an appendix.Data abstraction
Data routinely abstracted from studies are: study design,
population characteristics, eligibility criteria, interven-
tions, numbers randomized/treated and analyzed, and
results. Abstraction is performed by one reviewer and
independently checked by another; differences are
resolved by consensus. We record intention-to-treat
results when reported. If not reported, but loss to
follow-up was very small (< 5%), we note that they were
modified intention-to-treat results.Quality assessment of individual studies
Historically, to assess quality (i.e., internal validity or risk
of bias) of trials, cohort studies, and case-control studies,
we have applied predefined criteria that are based on
those used by the US Preventive Services Task Force and
the (UK) National Health Service Centre for Reviews
and Dissemination [17,18]. Studies that have a fatal flaw
are rated poor quality; studies that meet all criteria are
rated good quality; the remainder are rated fair quality.
As the fair-quality category is broad, studies with this
rating vary in their strengths and weaknesses— the
results of some fair-quality studies are likely to be valid,
while others are only possibly valid. A poor-quality study
is not valid and the results are at least as likely to reflect
flaws in the study design as a true difference among the
compared drugs. A fatal flaw may be reflected by one as-
pect introducing a high risk of bias or by failure to meet
combinations of items of the quality assessment check-
list. An example would be a study with a high attrition
(e.g., 60%) combined with inadequate handling of miss-
ing data (e.g., analyses based on observed events). A par-
ticular study might receive different ratings for different
outcomes.
The items assessed for trials, observational studies,
and systematic reviews are shown in Table 1. Each study
is assessed by two reviewers, with disagreements
resolved through consensus. There are currently no
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single-group studies.
The EPC program has recently updated their recom-
mendations on assessing the internal validity of studies
[19]. While the revised guidance continues to allow EPCs
to choose tools that evaluate the broader concept of
quality such as the one we use in DERP, it emphasizes
approaches that focus on the “risk of bias” of studies.
Evidence synthesis
Studies are stratified by key question and study quality.
The best evidence informs the synthesis that will address
each key question. Studies that evaluate one drug against
another provide direct evidence of comparative benefits
and harms and are preferred over indirect comparisons.
Similarly, studies of effectiveness and long-term or
serious harms outcomes are preferred over studies of
efficacy and short-term tolerability. Data from indirect
comparisons are used to support direct comparisons and
as the primary comparison when no direct comparisons
exist. Based on a number of statistical assumptions, in-
direct comparisons are interpreted with caution; among
their defects is a greatly reduced statistical power to
detect differences among groups [3,13,20,21]. Mixed
treatment comparisons meta-analysis (network meta-ana-
lyses) is a relatively new method that allows incorporation
of both direct and indirect comparisons in a single ana-
lysis and can be useful to allow for inclusion of all poten-
tially relevant data (e.g., from both placebo-controlled and
head-to-head trials) [22,23].
Evidence tables report study characteristics, quality
ratings, and findings of included studies. Key findings of
the review are encapsulated in “summary bullets”Table 1 Drug Effectiveness Review Project (DERP): Quality ass
Study design Controlled clinical trial Observational stu
Quality
Assessment
Criteria
•Randomization adequate? •Non-biased select
• Allocation concealment adequate? •High overall loss t
differential loss to
•Groups similar at baseline?
•Outcomes pre-spe
defined?•Eligibility criteria specified?
•Ascertainment tec
adequately describ
•Outcome assessors masked?
•Care provider masked? •Non-biased and a
ascertainment me
•Patient masked?
•ITT-analysis? •Statistical analysis
confounders?
•Maintenance of comparable groups?
•Adequate duratio
•Acceptable levels of crossovers,
adherence, and contamination?
•Overall and between-group attrition
acceptable?
Abbreviations: ITT intention-to-treat.(followed by a detailed discussion of the evidence) and
in a summary table at the end of the report.
Quantitative synthesis
For meta-analysis we follow the AHRQ EPC Methods
Guide recommendations [3]. In brief, to determine
whether meta-analysis can be meaningfully performed,
we consider the quality of the studies and the variation
in PICOTS. The Q statistic and the I2 are calculated to
assess statistical heterogeneity among studies and our in-
terpretation of the importance of observed heterogeneity
depends on the magnitude and direction of effects and
on the strength of evidence for heterogeneity [24-26]. If
significant statistical heterogeneity is identified, potential
sources can be examined by analysis of subgroups of
study design characteristics, study quality, patient popu-
lation, and variation in interventions, beyond those iden-
tified a priori. Meta-regression models may be used to
formally test for differences among subgroups with re-
spect to outcomes [27,28]. We prefer random-effects
models to estimate pooled effects because we believe it
provides a more conservative estimate, allowing for
some inter-study variation. A fixed effect model is used
in cases where inter-study variation is not expected (e.g.,
two very similar trials). Other analyses, including
adjusted indirect meta-analysis and a mixed treatment
effect model (network meta-analysis), are considered in
consultation with experienced statisticians. To date,
eight DERP reports have conducted indirect comparison
or network meta-analyses. When synthesizing unpub-
lished evidence, investigators conduct sensitivity analyses
where possible to assess any apparent reporting bias.
Poor-quality studies are not combined with fair- andessment criteria checklists by study design
dy Systematic review
ion? •Report clear review question, state inclusion and
exclusion criteria of primary studies?
o follow-up or
follow-up?
cified and •Substantial effort to find relevant research?
hniques
ed?
•Adequate assessment of validity of included
studies?
dequate
thods?
•Sufficient detail of individual studies presented?
of potential
•Primary studies summarized appropriately?
n of follow-up?
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added as part of sensitivity analyses.
Grading the strength of the evidence
Strength of evidence is assessed for the main outcomes
of each key question, generally by following the ap-
proach suggested by the EPC Methods Guide [3]. Using
the EPC approach, reviewers assign grades of high, mod-
erate, low, or insufficient to describe their confidence in
the strength of the evidence. At minimum, strength of
evidence grades take into account the number and se-
verity of limitations in risk of bias, consistency, direct-
ness, and precision. Strength of evidence ratings
typically focus on a subset of the outcomes that are most
important to the priorities of the DERP participants.
Representatives of the DERP organizations, and clinical
advisors, act as proxies for patients’ views on which
health outcomes are most important. Evidence from
poor-quality studies does not contribute to the assess-
ment of strength of evidence. The main findings and the
strength of the evidence for each key question are sum-
marized in a table at the end of the report, while the in-
dividual assessments of strength of evidence for each
outcome are included in an appendix. DERP reports
have always included an assessment of the quality of the
body of evidence; prior to adopting these outcome-based
methods, we used the key-question-based methods of
the United States Preventive Services Task Force [18].
We found the key-question-based method is simpler to
convey to policy-makers, although clinicians appreciate
the nuance of the outcome-based method.
Applicability
The applicability of the evidence related to each key
question is described in terms of populations and inter-
ventions to which the evidence applies. Exceptions –
groups or interventions to which the evidence does not
apply – are specified. Further consideration of how the
evidence applies to each organization’s local population
is left to the local decision-makers, with EPC investiga-
tors available to respond to questions.
Peer review and public comment
DERP reports are subject to peer review and public
comment prior to finalization. The participating organi-
zations also review the reports and provide comments to
the investigators. These processes help to optimize com-
pleteness and minimize bias in the final report. Peer
reviewers are identified by professional societies,
acknowledged expertise in a particular field, prominent
authorship in the published literature, or participation as
a Clinical Advisory Group member. For two weeks, draft
reports are posted to the public DERP Web site for pub-
lic comment. Manufacturers and groups of individualswith expressed interest in the topic are notified before
the posting and a mean of 2.7 sets (range 1–11) were
received per draft. The investigators are responsible for
documenting a resolution for each comment. The par-
ticipating organizations are the final arbiters of whether
comments have been adequately addressed. Typical
comments received are suggestions to add additional
studies (a small number that our searches missed but
more often studies that do not meet eligibility criteria)
and corrections to recorded details of individual studies
(e.g., the sample size and the percent in a particular
demographic group).
Updating reports
The participating organizations consider report updates
annually. This decision is based on an EPC-produced
scan that identifies new trials, drugs, approved indica-
tions, or serious harms relevant to the key questions of a
report. The report update process is as for an original
report. FDA approval of relevant new drugs is the most
common impetus for updating [29]. In the last year,
DERP has begun Single Drug Addendums to handle
situations where a new drug has become available very
soon after a report has been completed. These adden-
dums supplement the complete report until a full update
is commissioned and are produced on a 3-month
timeline.
Interaction with participating organizations
Once a report is produced, participants use them in mak-
ing evidence-based decisions on drugs in their respective
programs and investigators are available upon request to
present an overview of findings and to answer questions.
The investigators have found these interactions, monthly
phone conferences, and biannual meetings to be of great
value in identifying and understanding the needs of
policy-makers that use DERP reports. Lessons learned
through these interactions and from surveys about the
organizations’ opinions on various aspects of the project,
including the research reports, directly impact future
reports. Changes made to the methodology of reports
based on these interactions include 1) broadening the
scope to include multiple drug classes; 2) the creation of
Single Drug Addenda as noted above; 3) creation of
“black box warnings” appendices that do not qualify as
evidence in the review but are needed by the participants
in making decisions; and 4) formatting of summary ma-
terial (e.g. executive summaries and slides) to fit the
needs of the state Medicaid administrators, among
others.
Discussion
DERP’s current evidence review methods were devel-
oped primarily to meet the needs of State Medicaid
McDonagh et al. BMC Medical Research Methodology 2012, 12:140 Page 10 of 11
http://www.biomedcentral.com/1471-2288/12/140programs for informing evidence-based health policy
decisions using public processes. Development of these
methods began prior to the existence of the current
Methods Guide for EPCs. While many methods are now
congruent, there are nuances where DERP methodology
is explicit rather than allowing selection from multiple
options, largely due to having a specific audience. After
9 years of experience with DERP, we view the advantages
of these methods to be:
1. Incorporating input from the participants makes the
reports more useful to them for making policy
decisions,
2. Encouraging transparency through outside evaluation
of work quality and independent assessment for any
risk for bias,
3. Inviting public comment at the initial stages and
again near the final stages of the review allows for
consideration of viewpoints beyond those of
academic peer reviewers and the participants of
DERP,
4. Using a regular process to scan for new, important
developments in a given topic area allows for the
best use of participant funds, and
5. Providing specialized summary documents, for
example slide sets and executive summaries with new
information highlighted to increase the usefulness of
the reports for the participants.
While other groups may need to modify the approach
depending on the ultimate users of their work, we rec-
ommend that organizations producing comparative ef-
fectiveness reviews to inform health policy decisions
draw on the insights of policy-makers to develop and re-
fine evidence review methods. Our methods may not be
directly transferrable to topics other than comparative ef-
fectiveness reviews of pharmaceuticals, such as nonphar-
macological interventions or assessment of prognostic
and diagnostic tools, which may require special metho-
dologic features.
Conclusions
DERP has developed a timely and efficient method of
creating high-quality systematic reviews designed to
meet the needs of policy-makers. DERP continues to be
an innovator in methods that involve stakeholders. The
recent Institute of Medicine report [30] on conducting
systematic reviews reflects the DERP experience –
recommending direct and continuing communication
with policy-makers, flexibility in responding to new
situations, and responsiveness to emerging methods in
comparative effectiveness reviews. DERP has seen these
methods develop over the past 9 years. The result is a
series of comparative drug effectiveness reports thathave direct impact on policy decisions, reflected by the
ongoing financial support of the constituent organiza-
tions. Ongoing collaboration across organizations that
generate systematic reviews and the policy-makers that
use them will be essential to enhancing and disseminat-
ing high-quality methods for this work.
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